13 December 2019 - Vertex Pharmaceuticals today confirmed that, following recent collaborative discussions, it has negotiated an agreement with the Health Service Executive in the Republic of Ireland to expand the existing long-term cystic fibrosis reimbursement agreement to include the triple combination regimen (elexacaftor, tezacaftor and ivacaftor), which is under review and pending approval by the European Medicines Agency, for all eligible patients ages 12 and older in line with the potential future licensed indication.

This expands the existing agreement which had already included access to current and future Vertex medicines for people in Ireland with cystic fibrosis of any age who:

• Have one of the specified mutations as included in the Kalydeco marketing authorization (G551D, G551S, S549R, G1244E, S1251N, G1349D, S1255P, G178R or S549N) or
• Are homozygous for the F508del mutation or
• Are heterozygous for the F508del mutation and have a specified mutation (P67L, D579G, D1152H, R117C, 711+3A→G, 2789+5G→A, L206W, S945L, 3272-26A→G, R352Q, S977F, 3849+10kbC→T, A455E or R1070W) and people ages 18 and older and have an R117H mutation.

Read Vertex Pharmaceuticals press release